Clinical Trial

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

Name: Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma — clinical trial record (NCT07018050)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of the study is to compare the efficacy of QLS32105 (SC) in combination with Pomalidomide, and QLS32105 (SC) in combination with QL2109 or Daratumumab, and QLS32105 (SC) in combination with QL2109 or Daratumumab and Pomalidomide, and QLS32105(SC) in combination with Bortezomib and Lenalidomide.

Trial Details

NCT Number	NCT07018050
Lead Sponsor	Qilu Pharmaceutical Co., Ltd.
Conditions	Relapsed or Refractory Multiple Myeloma
Enrollment	160 participants
Start Date	2025-09-12
Primary Completion	2027-11 (estimated)
Study Completion	2028-07 (estimated)
Updated on ClinicalTrials.gov	2026-06-08